Identification and characterization of in vitro metabolites of 2-[2'- (dimethylamino)ethyl]-1,2-dihydro-3h-dibenz[de,h]isoquinoline-1,3-dione (azonafide)

Craig A. Mayr, Salah M. Sami, William A. Remers, Robert T Dorr

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Azonafide (2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de, h]isoquinoline-1,3-dione) is the parent of a new series of anthracene- containing antitumor agents. Its structure is based on amonafide but lacks a primary amine and has an anthracene chromophore rather than a naphthalene chromophore. Using a rat liver cytosol incubation and HPLC/MS detection, we have identified four metabolites resulting from in vitro metabolism of azonafide. These alkyl-modified derivatives include a mono- and a di-N'- desmethyl metabolite, an N'-oxide metabolite, and a carboxylic acid metabolite. Purified samples of these metabolites were analyzed for cytotoxic activity using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium vital dye (mitochondrial reductase) assay and for inhibition of topoisomerase II (TOPO II) using a cell-free enzymatic system. Each metabolite had decreased cytotoxicity relative to azonafide with the following relative potencies in descending order the mono-N'-desmethyl metabolite, di-N'- desmethyl metabolite, the N-oxide metabolite, and the carboxylic acid metabolite. Similarly, the N'-desmethyl metabolites retained TOPO II inhibitory activity but with lower potency then azonafide. The N-oxide and carboxylic acid metabolites did not inhibit TOPO II at 0.05 and 0.5 μg/ml, respectively. Thus, metabolism of azonafide by rat liver cytosol represents a detoxification pathway rather than a bioactivation scheme for this DNA intercalator.

Original languageEnglish (US)
Pages (from-to)105-109
Number of pages5
JournalDrug Metabolism and Disposition
Volume26
Issue number2
StatePublished - Feb 1998

Fingerprint

Metabolites
Type II DNA Topoisomerase
Carboxylic Acids
Oxides
amonafide
Cytosol
Intercalating Agents
Cell-Free System
Liver
Antineoplastic Agents
Amines
Chromophores
Oxidoreductases
Metabolism
Coloring Agents
High Pressure Liquid Chromatography
isoquinoline
azonafide
In Vitro Techniques
Rats

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Identification and characterization of in vitro metabolites of 2-[2'- (dimethylamino)ethyl]-1,2-dihydro-3h-dibenz[de,h]isoquinoline-1,3-dione (azonafide). / Mayr, Craig A.; Sami, Salah M.; Remers, William A.; Dorr, Robert T.

In: Drug Metabolism and Disposition, Vol. 26, No. 2, 02.1998, p. 105-109.

Research output: Contribution to journalArticle

@article{6ce638455040481592db40fd2ea5bf74,
title = "Identification and characterization of in vitro metabolites of 2-[2'- (dimethylamino)ethyl]-1,2-dihydro-3h-dibenz[de,h]isoquinoline-1,3-dione (azonafide)",
abstract = "Azonafide (2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de, h]isoquinoline-1,3-dione) is the parent of a new series of anthracene- containing antitumor agents. Its structure is based on amonafide but lacks a primary amine and has an anthracene chromophore rather than a naphthalene chromophore. Using a rat liver cytosol incubation and HPLC/MS detection, we have identified four metabolites resulting from in vitro metabolism of azonafide. These alkyl-modified derivatives include a mono- and a di-N'- desmethyl metabolite, an N'-oxide metabolite, and a carboxylic acid metabolite. Purified samples of these metabolites were analyzed for cytotoxic activity using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium vital dye (mitochondrial reductase) assay and for inhibition of topoisomerase II (TOPO II) using a cell-free enzymatic system. Each metabolite had decreased cytotoxicity relative to azonafide with the following relative potencies in descending order the mono-N'-desmethyl metabolite, di-N'- desmethyl metabolite, the N-oxide metabolite, and the carboxylic acid metabolite. Similarly, the N'-desmethyl metabolites retained TOPO II inhibitory activity but with lower potency then azonafide. The N-oxide and carboxylic acid metabolites did not inhibit TOPO II at 0.05 and 0.5 μg/ml, respectively. Thus, metabolism of azonafide by rat liver cytosol represents a detoxification pathway rather than a bioactivation scheme for this DNA intercalator.",
author = "Mayr, {Craig A.} and Sami, {Salah M.} and Remers, {William A.} and Dorr, {Robert T}",
year = "1998",
month = "2",
language = "English (US)",
volume = "26",
pages = "105--109",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Identification and characterization of in vitro metabolites of 2-[2'- (dimethylamino)ethyl]-1,2-dihydro-3h-dibenz[de,h]isoquinoline-1,3-dione (azonafide)

AU - Mayr, Craig A.

AU - Sami, Salah M.

AU - Remers, William A.

AU - Dorr, Robert T

PY - 1998/2

Y1 - 1998/2

N2 - Azonafide (2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de, h]isoquinoline-1,3-dione) is the parent of a new series of anthracene- containing antitumor agents. Its structure is based on amonafide but lacks a primary amine and has an anthracene chromophore rather than a naphthalene chromophore. Using a rat liver cytosol incubation and HPLC/MS detection, we have identified four metabolites resulting from in vitro metabolism of azonafide. These alkyl-modified derivatives include a mono- and a di-N'- desmethyl metabolite, an N'-oxide metabolite, and a carboxylic acid metabolite. Purified samples of these metabolites were analyzed for cytotoxic activity using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium vital dye (mitochondrial reductase) assay and for inhibition of topoisomerase II (TOPO II) using a cell-free enzymatic system. Each metabolite had decreased cytotoxicity relative to azonafide with the following relative potencies in descending order the mono-N'-desmethyl metabolite, di-N'- desmethyl metabolite, the N-oxide metabolite, and the carboxylic acid metabolite. Similarly, the N'-desmethyl metabolites retained TOPO II inhibitory activity but with lower potency then azonafide. The N-oxide and carboxylic acid metabolites did not inhibit TOPO II at 0.05 and 0.5 μg/ml, respectively. Thus, metabolism of azonafide by rat liver cytosol represents a detoxification pathway rather than a bioactivation scheme for this DNA intercalator.

AB - Azonafide (2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de, h]isoquinoline-1,3-dione) is the parent of a new series of anthracene- containing antitumor agents. Its structure is based on amonafide but lacks a primary amine and has an anthracene chromophore rather than a naphthalene chromophore. Using a rat liver cytosol incubation and HPLC/MS detection, we have identified four metabolites resulting from in vitro metabolism of azonafide. These alkyl-modified derivatives include a mono- and a di-N'- desmethyl metabolite, an N'-oxide metabolite, and a carboxylic acid metabolite. Purified samples of these metabolites were analyzed for cytotoxic activity using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium vital dye (mitochondrial reductase) assay and for inhibition of topoisomerase II (TOPO II) using a cell-free enzymatic system. Each metabolite had decreased cytotoxicity relative to azonafide with the following relative potencies in descending order the mono-N'-desmethyl metabolite, di-N'- desmethyl metabolite, the N-oxide metabolite, and the carboxylic acid metabolite. Similarly, the N'-desmethyl metabolites retained TOPO II inhibitory activity but with lower potency then azonafide. The N-oxide and carboxylic acid metabolites did not inhibit TOPO II at 0.05 and 0.5 μg/ml, respectively. Thus, metabolism of azonafide by rat liver cytosol represents a detoxification pathway rather than a bioactivation scheme for this DNA intercalator.

UR - http://www.scopus.com/inward/record.url?scp=0031938780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031938780&partnerID=8YFLogxK

M3 - Article

C2 - 9456295

AN - SCOPUS:0031938780

VL - 26

SP - 105

EP - 109

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 2

ER -